Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 29
Tirzepatide vs semaglutide: real-world data
A 511-patient real-world study in Mayo Clinic Proceedings found tirzepatide produced 16.6% vs 13.4% mean weight loss for semaglutide over 12 months.
Bofanglutide vs semaglutide in Chinese T2D
Ann Intern Med Phase 2b: bofanglutide 18 mg biweekly cut HbA1c by 2.28 points versus 1.60 for semaglutide 1 mg weekly in Chinese patients with type 2 diabetes.
BPC-157 and TB-500 for injury recovery
BPC-157 and TB-500 show tissue-repair effects in animal models, but no human randomised controlled trial exists for either peptide in musculoskeletal injury.
CagriSema pen usability: the study results
A 150-person study tested whether adults with overweight or diabetes could use the CagriSema dual-chamber autoinjector correctly after 3 minutes of training.
CircRNA with full nucleoside modification
A Fudan University circRNA platform combines nucleoside modification with rolling-circle translation, matching semaglutide in obese mice.
GLP-1 drugs in Medicaid: the coverage gap
Most US Medicaid programs restrict or exclude GLP-1 obesity drugs. Here is what the research says about who gets access and why coverage varies by state.
Health Canada vs FDA: approval paths
A 2026 JGIM study compares how Health Canada and the FDA use expedited pathways, with implications for Canadian patients waiting on GLP-1 approvals.
PT-141 in Germany: what the law says
Bremelanotide has no EMA or BfArM marketing authorisation. In Germany, the only lawful route is a physician-arranged named-patient import under AMG §73.
PT-141 side effects: what the trials report
The RECONNECT Phase 3 trials and the Vyleesi label put adverse-event rates on the record. Nausea leads at 40%; here is what else the data shows.
Is PT-141 prohibited in sport? WADA status
PT-141 (bremelanotide) does not appear by name on the WADA Prohibited List. Here is what athletes need to verify before drawing any conclusions.
What is PT-141? A plain-English explainer
PT-141 (bremelanotide, brand name Vyleesi) is a melanocortin receptor agonist with one FDA-approved indication and no EU marketing authorisation.
Retatrutide: dose ranges from the trials
Two Phase 2 trials tested retatrutide from 0.5 mg to 12 mg weekly. Here is what each trial administered, trial by trial.